ArticleRevista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT
Telemedicine minimum viable product for post-exposure prophylaxis to biological material in the COVID-19 pandemic.
Article in Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The COVID-19 pandemic brought new challenges for health services. The follow-up of cases of exposure to biological material is regulated by protocols of the Ministry of Health in Brazil. Telemedicine can be useful in maintaining appointments and reducing patient crowding. Objectives: To describe the development and implementation of telemedicine as a minimum viable product to care for victims of exposure to biological material in the context of the COVID-19 pandemic, in a reference service in northeastern Brazil. Methods: Descriptive study of the development of a minimum viable telemedicine product, seeking testimony from those involved and reviewing the script and tools used. Results: The telemedicine system was developed as a minimum viable product and worked asynchronously, being developed by integrating the WhatsApp Business, YouTube and Google Forms platforms and associating them with Excel and Word using database and direct mail tools, in addition to electronic equipment, cell phone, laptop, printer and scanner, and provided the follow-up of 742 cases of exposure to biological material from July 2020 to July 2021. Conclusions: The integration of tools already available on the internet allows a professional outside the field of information technology to develop a minimum viable telemedicine product, aiming to maintain health care and avoid the crowding of patients in outpatient clinics. We suggest the development of a robust tool that integrates several routines for monitoring cases of exposure to biological material.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.